Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Medpace Holdings Inc (MEDP) vs D Wave Quantum Inc (QBTS) Price & Performance

Medpace Holdings IncTrade
D Wave Quantum IncTrade

Price performance (Past 24H)

Key statistics

Medpace Holdings Inc vs D Wave Quantum Inc — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while D Wave Quantum Inc trades at $20.63 (market cap $7.53B). The key difference: Medpace Holdings Inc is far larger — about 2.2× D Wave Quantum Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals.

MEDPQBTS
Market Cap
$16.90B$7.53B
Sector
TechnologyTechnology
52-Week High
$620.59$44.78
52-Week Low
$393.42$12.98
Enterprise Value
$16.52B$7.04B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Medpace Holdings Inc

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.

D Wave Quantum Inc

D-Wave Quantum (QBTS) trades at $20.75, up 2.77% today, but faces bearish technical signals amid mixed earnings performance. The company reported a Q2 2026 loss of $0.10 per share, missing estimates, while revenue remained flat at $3.1 million. Despite negative profitability metrics, analyst consensus remains unanimously bullish with a $38.29 price target, reflecting optimism about quantum computing adoption and strong bookings growth.

The stock presents high-risk speculative potential with significant valuation concerns trading at 584x sales. While institutional interest and government funding support long-term quantum computing prospects, persistent losses and declining revenue create substantial execution risk. Investors must weigh Wall Street optimism against fundamental weaknesses in this emerging technology play.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP

About D Wave Quantum Inc

D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.

Read more on QBTS